Xcout IntelEdgewise Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Edgewise Therapeutics among biotechnology companies — ranked by similarity to what Edgewise Therapeutics actually does, not by market-cap band.
Subscribe to see Edgewise Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Edgewise Therapeutics
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Edgewise Therapeutics at a glance
Edgewise Therapeutics is a biotechnology company headquartered in Boulder, United States. It is publicly listed (EWTX) with a market capitalisation of $4.2B. Xcout tracks 29 named people at Edgewise Therapeutics, including Kevin Koch (President, Chief Executive Officer & Director). Xcout recorded 30 job postings from Edgewise Therapeutics in the last 90 days.
Edgewise Therapeutics leadership
- Kevin KochPresident, Chief Executive Officer & Director
- Kevin Koch, Ph.D.President and Chief Executive Officer
- Behrad DerakhshanChief Operating Officer
- Behrad Derakhshan, Ph.D.Chief Operating Officer
- Michael NofiChief Financial Officer
- Joanne DonovanChief Medical Officer
23 more named people on record for Edgewise Therapeutics, with roles, board committees and tenure — see the full roster →
Edgewise Therapeutics funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $50M | 18 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Edgewise Therapeutics
Xcout recorded 30 job postings from Edgewise Therapeutics in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Edgewise Therapeutics's hiring signals →
Recent Edgewise Therapeutics news
- AcquisitionPharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
- AcquisitionPharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio - Pharmaceutical Executive
4 corporate events on record, with sources — see the full timeline →
Top 12 Edgewise Therapeutics competitors
Ranked by semantic similarity — how close each company is to Edgewise Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Biotech
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Similar biotechnology company
Myosana Therapeutics, Inc. is a biotechnology research company based in Seattle, Washington, pioneering non-viral gene therapy treatments for muscle diseases.
Similar biotechnology company
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Biotech
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Similar biotechnology company
EdiGene is a clinical-stage biotechnology company founded in 2015 that focuses on translating gene-editing technologies into therapeutic products. Headquartered in Beijing, China, the company also operates research and office facilities in locations such as Shanghai, Guangzhou, and the United States.
Similar biotechnology company
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Biotech
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Biotech
Mirador Therapeutics, Inc. is a clinical-stage precision medicine company headquartered in San Diego, California, focused on developing first- and best-in-class next-generation therapeutics.
Biotech
Circio Holding ASA is a biotechnology company that develops novel circular RNA and immunotherapy medicines, utilizing its proprietary circVec platform to enhance gene therapy for genetic diseases. It serves the biopharmaceutical sector and patients with genetic disorders by advancing clinical programs and engaging in research collaborations.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Edgewise Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Edgewise Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →